Depdc5 deficiency exacerbates alcohol-induced hepatic steatosis via suppression of PPARα pathway
Open Access
- 15 July 2021
- journal article
- research article
- Published by Springer Nature in Cell Death & Disease
- Vol. 12 (7) , 1-11
Abstract
Alcohol-related liver disease (ALD), a condition caused by alcohol overconsumption, occurs in three stages of liver injury including steatosis, hepatitis, and cirrhosis. DEP domain-containing protein 5 (DEPDC5), a component of GAP activities towards Rags 1 (GATOR1) complex, is a repressor of amino acid-sensing branch of the mammalian target of rapamycin complex 1 (mTORC1) pathway. In the current study, we found that aberrant activation of mTORC1 was likely attributed to the reduction of DEPDC5 in the livers of ethanol-fed mice or ALD patients. To further define the in vivo role of DEPDC5 in ALD development, we generated Depdc5 hepatocyte-specific knockout mouse model (Depdc5-LKO) in which mTORC1 pathway was constitutively activated through loss of the inhibitory effect of GATOR1. Hepatic Depdc5 ablation leads to mild hepatomegaly and liver injury and protects against diet-induced liver steatosis. In contrast, ethanol-fed Depdc5-LKO mice developed severe hepatic steatosis and inflammation. Pharmacological intervention with Torin 1 suppressed mTORC1 activity and remarkably ameliorated ethanol-induced hepatic steatosis and inflammation in both control and Depdc5-LKO mice. The pathological effect of sustained mTORC1 activity in ALD may be attributed to the suppression of peroxisome proliferator activated receptor α (PPARα), the master regulator of fatty acid oxidation in hepatocytes, because fenofibrate (PPARα agonist) treatment reverses ethanol-induced liver steatosis and inflammation in Depdc5-LKO mice. These findings provide novel insights into the in vivo role of hepatic DEPDC5 in the development of ALD.Keywords
This publication has 35 references indexed in Scilit:
- Kinome-wide Selectivity Profiling of ATP-competitive Mammalian Target of Rapamycin (mTOR) Inhibitors and Characterization of Their Binding KineticsJournal of Biological Chemistry, 2012
- Alcoholic Liver Disease: Pathogenesis and New Therapeutic TargetsGastroenterology, 2011
- mTOR Complex 1 Regulates Lipin 1 Localization to Control the SREBP PathwayCell, 2011
- Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriersNature Genetics, 2011
- Akt Stimulates Hepatic SREBP1c and Lipogenesis through Parallel mTORC1-Dependent and Independent PathwaysCell Metabolism, 2011
- Tuberous Sclerosis Complex-1 Deficiency Attenuates Diet-Induced Hepatic Lipid AccumulationPLOS ONE, 2011
- mTOR signaling at a glanceJournal of Cell Science, 2009
- An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1Journal of Biological Chemistry, 2009
- Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathwaysHuman Molecular Genetics, 2005
- Ethanol Induces Fatty Acid Synthesis Pathways by Activation of Sterol Regulatory Element-binding Protein (SREBP)Journal of Biological Chemistry, 2002